Numerous medical device news sources and industry executives have proclaimed renal denervation to be the top medical device breakthrough of the past two years, and for good reason. Hypertension is one of the most prevalent chronic conditions worldwide, with some studies estimating that 50% of the adult population globally will have the disease in the next 20 years. With limited effectiveness from pharmacotherapy, medical device therapy has the potential for significant adoption in the treatment of resistive hypertension and uncontrolled hypertension, once efficacy and cost-effectiveness are proven. Additionally, the degree of blood pressure reduction found in long-term clinical trials from such a well-tolerated procedure has generated notable optimism about the interventions application in other conditions where hyperactivity of the sympathetic nervous system plays a significant role, such as congestive heart failure.
While there is room for optimism and
excitement, there are also significant barriers that the technology must
overcome before it can see the widespread adoption that industry professionals
want. One of the most threatening issues involves ambulatory blood pressure
readings and how they could severely tarnish the purported impact the
technology has on reducing blood pressure. Thus, a lot will depend on the
quality of the data produced by the first randomized clinical trial from
Medtronic in 2014, which includes this measure. Additionally, the current
players in the market will have to face a bombardment of renal denervation
systems from startup companies that harness slightly different technologies,
offering advantages such as external denervation and non-generator-based
systems. Compounding this competitive landscape are different device categories
that aim to reduce blood pressure through completely different mechanisms, such
as carotid baroreceptor stimulation.
As this market becomes more
competitive, device makers are going to have to develop clinical
differentiators for their systems or else this market will quickly become
commoditized. Additionally, device manufacturers will have to seek additional
indications for their systems to help the market continue to grow. In light of
these impending challenges, GlobalData has produced a market research report,
MediPoint: Renal Denervation - Global Analysis and Market Forecasts. Utilizing
primary research with the leading adopters of the technology in the major
global economies and industry executives from the major players in the market,
as well as secondary research, this report offers a comprehensive analysis of
the current and future marketplace for these devices.
Highlights
Key Questions Answered
* The CEO of the current
market-leading company, Medtronic, has described renal denervation as a
long-term opportunity in hypertension and a slow-to-adopt [technology in
Europe]. (Q).How slow is the adoption of the procedure? (Q).When is the market
expected to see significant growth?
* In most countries renal
denervation is performed as an inpatient procedure, which is one of the major
factors in driving up the costs of the intervention. (Q).Which countries
perform the intervention on an inpatient basis? (Q).What is needed to make this
procedure be performed on an outpatient basis?
* Different countries incorporate
different teams of specialists when performing renal denervation. (Q).Which
countries are utilizing which specialists? (Q).Who do Key Opinion Leaders think
will be predominately performing this procedure in the future?
* Several major players in the
market have already developed second generations of their systems. (Q).What are
the most important product features and designs surgeons like about current
systems? (Q).What features would they like to see in future product iterations?
* 2014 is poised to be a very
important year for clinical trial results in the renal denervation market.
(Q).What are the key trials to follow in 2014 and how will their results impact
the adoption of these systems?
* Medtronic currently dominates the
renal denervation market. (Q).What is their market share in the major global
economies and which companies constitute the remainder of the market? (Q).How
will the market shares change in the next three years?
* Currently marketed renal
denervation systems are boasting similar efficacy and safety profiles and
similar average selling prices. (Q).What are the key marketing and sales
strategies current and future players can utilize to gain market share?
Reasons to buy
* What Do Physicians Think quotes
provide a unique insight into how healthcare professionals are reacting to
events within the industry, and what their responses could mean for industry
strategists. This information is essential for all strategic decision-makers in
every organization, allowing them to act on high-quality information.
To order this report:
US:
+1 866 325 7446
UK: +44 203 514 2363
India: +91 22 4098 7600
RELATED LINK:
RELATED VIDEO:
No comments:
Post a Comment